NCT03809260View on ClinicalTrials.gov

A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Human Microbiome
Interventions
DRUG

Metformin (part 1)

1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).

DRUG

Vancomycin

11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid

DRUG

Metformin (part 2)

1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)

Trial Locations (1)

03080

SNUBH Clinical trial centor, Seongnam-si

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT03809260 - A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin | Biotech Hunter | Biotech Hunter